630057-39-5
Chemical Structure
Neoprzewaquinone A
- CAS No.: 630057-39-5
- Formula:C36H28O6
- Molecular Weight:556.60
InChIKey: SXQCYGZVSVUMEL-QGMBQPNBSA-N
SMILES: O=C1C2=C(CC/C=C(C3=CC=C(C4=C(C(C)=CO4)C5=O)C(C5=O)=C3CCCC6=C)\C)C6=CC=C2C7=C(C(C)=CO7)C1=O
Biological Activity: Neoprzewaquinone (NEO) is an orally active phenanthraquinone derivative isolated from Salvia miltiorrhiza Bunge. Neoprzewaquinone A inhibits IL-15Rα, blocks the ROCK2/STAT3 pathway to impair the migration and invasion abilities of triple-negative breast cancer cells; induces apoptosis of hepatocellular carcinoma cells by inhibiting the PI3K-AKT pathway; suppresses LPS-induced inflammation via binding to TLR4/MD2, and inhibits IL-15-induced proliferation, migration and phagocytosis of microglial cells; protects osteoblasts from mitochondrial dysfunction and apoptosis in diabetic osteoporosis by activating PRKD2 and the ELF5/PRKD2/PI3K/AKT/mTOR axis. Neoprzewaquinone A can be used in the research of diseases including rheumatoid arthritis, hepatocellular carcinoma, diabetic osteoporosis and triple-negative breast cancer[1][2][3][4][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Neoprzewaquinone A | 99.26% | Neoprzewaquinone (NEO) is an orally active phenanthraquinone derivative isolated from Salvia miltiorrhiza Bunge. Neoprzewaquinone A inhibits IL-15Rα, blocks the ROCK2/STAT3 pathway to impair the migration and invasion abilities of triple-negative breast cancer cells; induces apoptosis of hepatocellular carcinoma cells by inhibiting the PI3K-AKT pathway; suppresses LPS-induced inflammation via binding to TLR4/MD2, and inhibits IL-15-induced proliferation, migration and phagocytosis of microglial cells; protects osteoblasts from mitochondrial dysfunction and apoptosis in diabetic osteoporosis by activating PRKD2 and the ELF5/PRKD2/PI3K/AKT/mTOR axis. Neoprzewaquinone A can be used in the research of diseases including rheumatoid arthritis, hepatocellular carcinoma, diabetic osteoporosis and triple-negative breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liu Q, et al. Network pharmacology and virtual screening suggest neoprzewaquinone a as a potential therapeutic agent for rheumatoid arthritis, validated in fibroblast-like synoviocytes and collagen-induced arthritis models. International immunopharmacology. 2026 Aug 01;187:117224.
- [2]. Zhang C, et al. Neoprzewaquinone A suppresses hepatocellular carcinoma through promoting the ubiquitin-related degradation of EGFR and inhibiting PI3K-AKT pathway. European journal of pharmacology. 2025 Nov 15;1007:178274. [Content Brief]
- [3]. Chen R, et al. Targeting Mitochondrial Dysfunction to Treat Diabetic Osteoporosis: Role of Neoprzewaquinone A. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2026 Jul 25;157:158370.
- [4]. Zhao G, et al. Neoprzewaquinone A Inhibits Breast Cancer Cell Migration and Promotes Smooth Muscle Relaxation by Targeting PIM1 to Block ROCK2/STAT3 Pathway. International journal of molecular sciences. 2023 Mar 13;24(6):5464.
- [6]. Wang H, et al. Neoprzewaquinone A alters the migration, phagocytosis and energy metabolism of IL-15-induced HMC3 cells. Molecular immunology. 2024 Oct;174:11-17.
- [7]. van der Meer JW, et al. Abstract!. The Netherlands journal of medicine. 2002 Dec;60(11):418. [Content Brief]
